Company Overview & Financial Performance - Inspire Medical Systems highlights a significant underpenetrated U S market valued at over $10 billion[7] - The company reported revenue of over $800 million in 2024, marking a 28% year-over-year growth[7, 10] - The company has surpassed 100,000 patients receiving Inspire therapy[7, 75] - The company's gross margin for the first quarter was 84.7%[75] - FY2025 revenue is projected to be in the range of $940 million to $955 million, representing a 17%-19% growth over FY2024[70] Inspire Therapy & Market Dynamics - The company has reimbursement coverage in all 50 states, covering over 300 million U S lives[7, 9] - The domestic OSA market presents a substantial opportunity, with approximately 500,000 Inspire-eligible individuals[25] - Inspire patients experience a median AHI reduction from 33 events/hr at baseline to 10.2 events/hr at 12 months[44] - 91% of patients say Inspire is better compared against their previous experience with CPAP[47] GLP-1s and OSA - Claims data identified over 1,500 patients who were on a GLP-1 at the time of Inspire implant[122] - The BMI of Inspire patients was roughly 20% lower at the time of implant than all other OSA patients at the time of their OSA Dx[123]

Core Viewpoint - Vivos Therapeutics, Inc. is acquiring The Sleep Center of Nevada to expand its obstructive sleep apnea (OSA) treatment offerings in the Las Vegas area, enhancing its market position and patient access to its FDA-cleared oral appliance treatments [1][3][6]. Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on developing non-invasive treatments for OSA and related sleep disorders, with FDA-cleared devices for both adults and children [8][10]. - The Sleep Center of Nevada, founded in 2008, is the largest operator of medical sleep centers in Nevada, serving approximately 3,000 new patients monthly and generating high seven-figure annual revenues [4][8]. Acquisition Details - Vivos will pay up to $9 million for SCN's operating assets, including $6 million in cash and $1.5 million in Vivos common stock at closing, with an additional $1.5 million contingent on future financial milestones [5][6]. - The acquisition is expected to close later this quarter or in the third quarter, subject to customary conditions [2][5]. Strategic Implications - The acquisition aligns with Vivos' mission to provide accessible, clinically proven OSA treatments, leveraging SCN's infrastructure to enhance service offerings and patient acceptance [3][6]. - Vivos anticipates that SCN patients will prefer its treatment options over traditional CPAP devices, as evidenced by a previous strategic alliance where two-thirds of OSA patients chose Vivos treatments [6][7]. Market Context - OSA affects over 1 billion people globally, with a significant portion undiagnosed, indicating a substantial market opportunity for effective treatment alternatives [9]. - The acquisition is part of Vivos' broader strategy to create collaborations with key players in the sleep clinic sector, aiming to reach a larger patient volume and improve cash flow [7][9].